We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Blood Cancer Trials May Use Minimal Residual Disease Measures as Endpoints, Guidance Says
Blood Cancer Trials May Use Minimal Residual Disease Measures as Endpoints, Guidance Says
Trials for hematologic malignancies can use measures of minimal residual disease (MRD) as a biomarker, according to a final guidance issued by the FDA that specifies the types and uses of measures the agency will accept.